PDL Advances Ulcerative Colitis Treatment Nuvion Into Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm is still considering a potential partner for the monoclonal antibody.
You may also be interested in...
PDL Pulls The Plug On Nuvion Program After Phase III Failure
Interim analysis from a Phase III study of the investigational ulcerative colitis therapy shows insufficient efficacy and an inferior safety profile, company reports.
PDL Pulls The Plug On Nuvion Program After Phase III Failure
Interim analysis from a Phase III study of the investigational ulcerative colitis therapy shows insufficient efficacy and an inferior safety profile, company reports.
PDL BioPharma Product Sales Up 25 Percent On Cardene Growth
Firm is focused on lifecycle management for Cardene as well as partnering opportunities for investigational drugs ularitide and Nuvion, CEO says.